Antigenics: Down, but not out?

Article Abstract:

Garo Armen, CEO is working hard to pull its $425 million company Antigenics out of its downward spin, because of a cancer vaccine called Oncophage, whose clinical data is far from perfect. The company is trying to track the missing patients with the help of third party, though there is no surety that this would convince FDA to restart trial and states it would stop the Oncophage program if further analysis suggest that the compound does not work.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

An antibiotic to the rescue

Article Abstract:

A story about Jeff Alder from Cubist who turned Phase III failure of Cidecin to approval by FDA, for use in skin and tissue infections is narrated. Cidecin is one of the lead anti-infective compounds, which failed to treat community-acquired pneumonia (CAP), but was approved as Cubicin for treatment of skin and tissue infection as well as endocarditic condition.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

Testing transporters

Article Abstract:

The article discusses preclinical drug testing and the effects of these drugs on the metabolism and excretion profiles of small molecules in humans.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code: